Hyperspectral Retinal Imaging for Drusen Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means for in vivo imaging and quantification of autofluorescence in the eye to diagnose and monitor age-related macular degeneration (AMD), particularly in identifying drusen and its components, which are early signs of AMD.
Innovation Solution
A hyperspectral imaging system that administers short wavelength violet or blue light excitation signals to the retina and uses hyperspectral sensors to detect and analyze electromagnetic emissions spectra, identifying target spectra corresponding to drusen and quantifying their presence based on normative data to diagnose AMD and assess treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging methods are used to detect retinal fluorescence, then the device complexity is low, but the measurement precision and ability to identify drusen components is insufficient
Solution Approach 1:
The patent segments the detection process into multiple spectral bands, analyzing different wavelength ranges (400-490nm excitation, 450-580nm emission) to identify specific drusen components. The hyperspectral sensor divides the retinal fluorescence into multiple component emissions spectra, allowing precise identification of different fluorophores and their spatial distribution.
Solution Approach 2:
The patent changes the detection parameter from conventional single-wavelength or broad-spectrum imaging to hyperspectral imaging across multiple wavelengths. By administering excitation signals at specific wavelengths (400-490nm) and detecting emissions across a spectrum (450-580nm), the system transforms the detection approach to enable component-specific identification of drusen.
2Reliability
If quantitative analysis of drusen is performed to diagnose AMD, then the diagnostic accuracy is improved, but the difficulty of detecting and measuring increases
Solution Approach 1:
The patent implements a feedback mechanism where the detected electromagnetic emissions spectrum is compared against known spectral signatures of drusen components. The system identifies component emissions spectra, matches them to reference spectra, and quantifies the amount of each component present, providing feedback that enables accurate diagnosis and monitoring of AMD progression.
Solution Approach 2:
The patent uses the electromagnetic emissions spectrum as an intermediary between the drusen components and the diagnostic information. By detecting and analyzing the fluorescence emissions at specific wavelengths, the system translates the physical presence of drusen into quantifiable diagnostic data that indicates AMD severity and progression.
3Measurement precision
If hyperspectral imaging with multiple wavelengths is used, then the measurement precision and component identification capability are improved, but the use of energy and device complexity increase
Solution Approach 1:
The patent applies partial action by focusing the hyperspectral detection on specific wavelength ranges relevant to drusen fluorescence (400-490nm excitation, 450-580nm emission) rather than analyzing the entire electromagnetic spectrum. This targeted approach maintains measurement precision for drusen identification while reducing the energy and computational resources required compared to full-spectrum hyperspectral imaging.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection and quantification of drusen, facilitating accurate diagnosis and monitoring of AMD progression, as well as assessing the effectiveness of treatments, with improved sensitivity and specificity compared to existing techniques.
Implementation Method 1
The RPE has an innate autofluorescence; the normal pattern of this fluorescence is altered in AMD in characteristic ways.
Implementation Method 2
detecting, using one or more hyperspectral sensors, an electro magnetic emissions spectrum from the retina in response to the excitation signal
Data Source
AI summary
A system and method for in vivo detection and quantification of drusen present in the retina via administering an excitation signal to the retina of the eye and detecting an electromagnetic emissions spectrum from the retina in response to the excitation signal. The electromagnetic emissions spectrum may be used to identify a plurality of component emissions spectra, each component emissions spectrum corresponding to fluorescence from a component of the retina, one of the component emissions spectra corresponding to a target emissions spectrum.